Question explored with the scientific record
Hiv cure
The short version: no HIV cure exists. The evidence here is about managing the disease, not eliminating it.
The retrieved evidence is almost entirely about treating HIV-related complications, not curing HIV itself. You get case reports of people whose Kaposi's sarcoma [2], lymphomatoid granulomatosis [3], or Behçet's disease [1] went into remission when antiretroviral therapy (ART) restored their immune function. These show that ART can suppress HIV and let the immune system clear secondary infections. That is management, not cure.
The real cure research is about the viral reservoir. HIV hides in long-lived cells where ART cannot reach it. The evidence on elite controllers, people who suppress HIV naturally without drugs, shows what a cure would need to do. Elite controllers have very small viral reservoirs, about 20-fold smaller than people on ART [11]. Their intact proviruses are often integrated into non-genic DNA, which may keep them silent [11, 16]. But even in these rare individuals, replication-competent virus persists [11]. One study found that elite controllers actually have more coronary atherosclerosis than HIV-negative controls, suggesting that even natural control comes with a cost [10].
The Berlin patient, who received a stem cell transplant from a donor with a natural HIV-resistance mutation (CCR5-delta32), remains the only documented cure [19]. That approach is too dangerous and expensive for general use. Gene therapy to disrupt CCR5 in a patient's own cells is being tested [19]. Broadly neutralizing antibodies can suppress virus during treatment interruptions, but rebound still happens, driven by variants the antibodies cannot neutralize [21, 22]. NK cell activity, not T cells, seems to matter most for how fast the virus comes back [20].
My call: there is no cure for HIV. The evidence supports that ART can suppress the virus and prevent AIDS-related complications, but the latent reservoir persists in everyone. The only proven cure, a stem cell transplant, is not a practical treatment. Confidence: high.
Sources used 10
-
Remission of Behçet's disease and keratoconjunctivitis sicca in an HIV-infected patient treated with HAART
This study reports the first case of complete remission of Behçet's disease and keratoconjunctivitis sicca in an HIV-infected patient following highly active antiretroviral therapy (HAART).
DOI: 10.1258/095646204322764352 -
Kaposi's sarcoma in a HIV-positive patient
38-year-old HIV-positive man with Kaposi's sarcoma was diagnosed by biopsy and HHV-8 immunostaining and achieved remission after antiretroviral therapy followed by paclitaxel.
DOI: 10.53301/lw/176198 -
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient
This case report describes a 55-year-old woman with low-grade lymphomatoid granulomatosis (LYG) and newly diagnosed HIV, whose rapid immune recovery through antiretroviral therapy led to complete and sustained remission of LYG.
DOI: 10.1186/s12981-025-00717-9 -
Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers
This study investigates the prevalence of coronary atherosclerosis and immune activation in HIV-1 elite controllers compared to chronic HIV-1 patients and HIV-negative controls, revealing significantly higher atherosclerosis rates and immune activation markers in elite controlle…
DOI: 10.1097/QAD.0b013e32835a9950 -
Viral reservoirs in elite controllers of HIV-1 infection: Implications for HIV cure strategies
This review synthesizes current knowledge about viral reservoirs in HIV elite controllers, detailing how reservoirs are small yet contain replication-competent virus, how ongoing replication can occur in certain compartments, how proviral integration and clonal expansion shape t…
DOI: 10.1016/j.ebiom.2020.103118 -
Viral reservoir characteristics in lymphoid tissues of HIV-1 elite controllers
Longitudinal, paired analyses of HIV-1 reservoirs in blood and inguinal lymph nodes from two female elite controllers show substantially fewer and less diverse intact proviruses in lymphoid tissue than in blood, with reservoirs declining over time and predominantly non-genic int…
DOI: 10.1172/jci.insight.197308 -
The search for an HIV cure: tackling latent infection
A comprehensive review of strategies to eradicate latent HIV reservoirs and move toward a cure, covering ART-based latency reversal, the Berlin patient case, gene therapy, immune modulation, and the timing of interventions.
DOI: 10.1016/S1473-3099(13)70043-4 -
Immune correlates of HIV-1 rebound during broadly neutralizing antibody treatment in young children
NK cell subsets and KIR-HLA interactions correlate with HIV-1 rebound timing and reservoir dynamics after bnAb therapy in perinatally infected children, while HIV-specific T cell responses are weak and the proviral reservoir remains very small, implying NK-cell–mediated influenc…
DOI: 10.1172/JCI193912 -
Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir
This study defines a quantitative, immune-driven threshold (inhibitory potential at 10 mg/mL IgG, IP10mg/mL) that constrains rebound-competent HIV-1 proviruses, showing rebound during analytic treatment interruption arises from autologous antibody–resistant reservoir variants, w…
DOI: 10.64898/2025.12.07.692769 -
Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control
Broadly neutralizing antibody–driven HIV suppression during ART interruption triggers early innate immune activation and inflammatory pathways prior to rebound, potentially supporting post-intervention viral control without detectable HIV-specific T cell boosts in blood.
DOI: 10.64898/2026.05.29.728863